PPK/PD and individualized treatment of voriconazole in patients with liver dysfunction

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019472

Enrollment

Unknown

Registered

2018-11-12

Start date

2018-11-20

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive fungal infections

Interventions

Normal liver function group:Routine treatment with voriconazole

Liver dysfunction group:Routine treatment with voriconazole

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged at least 18 years; 2. Receiving intravenous voriconazole (Vfend) for prevention or treatment of invasive fungal infections.

Exclusion criteria

Exclusion criteria: 1. Absence of voriconazole plasma concentration; 2. Incomplete important dosing information or clinical data.

Design outcomes

Primary

Measure	Time frame
Plasma drug concentration;Clinical efficacy/outcomes;Adverse reaction rate;Clinical index;	—

Countries

China

Contacts

Public ContactChen Xiao

The First Affiliated Hospital of Sun Yat-sen University

frankwychen@hotmail.com+86 13924199635

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026